Angiogenesis and co-expressed of ER and c-erbB-2 (HER2/neu) protein in primary breast cancer patients: An analysis of 158 needle core biopsies

Romanian Journal of Morphology and Embryology

Volumn 49, Issue 4, 2008, Pages 469-478

  Vamesu S ^a  

^a Department of Pathology   (Romania)

Author keywords

Angiogenesis; Breast carcinoma; C erbB 2 (HER2 neu); ER; Needle breast core biopsy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST TUMOR; CARCINOMA; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; NEEDLE BIOPSY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, FINE-NEEDLE; BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTOR, ERBB-2; YOUNG ADULT;

EID: 70450105849     PISSN: 12200522     EISSN: 20668279     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. RIES L. A. G., KOSARY C. L., HANKEY B. F., MILLER B. A., EDWARDS B. K. (eds), SEER Cancer Statistics Review, 1973-1995, National Cancer Institute, Bethesda, MD, 1998.
2. BAILAR J. C. 3RD, GORNIK H. L., Cancer undefeated, N Engl J Med, 1997, 336(22):1569-1574.
3. LANDIS S. H., MURRAY T., BOLDEN S., WINGO P. A., Cancer statistics, 1999, CA Cancer J Clin, 1999, 49(1):8-31.
4. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group, Lancet, 1992, 339(8784):1-15.
5. KARRISON T. G., FERGUSON D. J., MEIER P., Dormancy of mammary carcinoma after mastectomy, J Natl Cancer Inst, 1999, 91(1):80-85.
6. SAPHNER T., TORMEY D. C., GRAY R., Annual hazard rates of recurrence for breast cancer after primary therapy, J Clin Oncol, 1996, 14(10):2738-2746.
7. GOLDHIRSCH A., WOOD W. C., GELBER R. D., COATES A. S., THÜRLIMANN B., SENN H. J., Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer, J Clin Oncol, 2003, 21(17):3357-3365.
8. COLEMAN R. E., Current and future status of adjuvant therapy for breast cancer, Cancer, 2003, 97(3 Suppl):880-886.
9. LAKE D. E., HUDIS C., Aromatase inhibitors in breast cancer: an update, Cancer Control, 2002, 9(6):490-498.
10. VOGEL C. L., COBLEIGH M. A., TRIPATHY D., GUTHEIL J. C., HARRIS L. N., FEHRENBACHER L., SLAMON D. J., MURPHY M., NOVOTNY W. F., BURCHMORE M., SHAK S., STEWART S. J., PRESS M., Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-over- expressing metastatic breast cancer, J Clin Oncol, 2002, 20(3):719-726.
11. PIKE A. C., BRZOZOWSKI A. M., HUBBARD R. E., A structural biologist's view of the oestrogen receptor, J Steroid Biochem Mol Biol, 2000, 74(5):261-268.
12. KHAN S. A., ROGERS M. A., KHURANA K. K., SIDDIQUI J. F., Oestrogen receptor expression in normal breast epithelium, Eur J Cancer, 2000, 36(Suppl 4):S27-S28.
13. SHOKER B. S., JARVIS C., CLARKE R. B., ANDERSON E., HEWLETT J., DAVIES M. P., SIBSON D. R., SLOANE J. P., Estrogen receptor-positive proliferating cells in the normal and precancerous breast, Am J Pathol, 1999, 155(6):1811-1815.
14. KHAN S. A., YEE K. A., KAPLAN C., SIDDIQUI J. F., Estrogen receptor alpha expression in normal human breast epithelium is consistent over time, Int J Cancer, 2002, 102(4):334-337.
15. BATTERSBY S., ROBERTSON B. J., ANDERSON T. J., KING R. J., MCPHERSON K., Influence of menstrual cycle, parity and oral contraceptive use on steroid hormone receptors in normal breast, Br J Cancer, 1992, 65(4):601-607.
16. SHAW J. A., UDOKANG K., MOSQUERA J. M., CHAUHAN H., JONES J. L., WALKER R. A., Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas, J Pathol, 2002, 198(4):450-457.
17. ARORA R., BADVE S., Effect of menstrual cycle on expression of estrogen and progesterone receptors in breast epithelium, Mod Pathol, 2003, 16:22A.
18. MOGGS J. G., ORPHANIDES G., Estrogen receptors: orchestrators of pleiotropic cellular responses, EMBO Rep, 2001, 2(9):775-781.
19. DIGIOVANNA M. P., Clinical significance of HER-2/neu overexpression: part I, PPO Updates, 1999, 13(9):1-10.
20. DIGIOVANNA M. P., Clinical significance of HER-2/neu overexpression: part II, PPO Updates, 1999, 13(10):1-14.
21. REESE D. M., SLAMON D. J., HER-2/neu signal transduction in human breast and ovarian cancer, Stem Cells, 1997, 15(1):1-8.
22. HUNG M. C., LAU Y. K., Basic science of HER-2/neu: a review, Semin Oncol, 1999, 26(4 Suppl 12):51-59.
23. SLIWKOWSKI M. X., LOFGREN J. A., LEWIS G. D., HOTALING T. E., FENDLY B. M., FOX J. A., Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin), Semin Oncol, 1999, 26(4 Suppl 12):60-70.
24. FOLKMAN J., Role of angiogenesis in tumor growth and metastasis, Semin Oncol, 2002, 29(6 Suppl 16):15-18.
25. FOLKMAN J., Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical application of research on angiogenesis, N Engl J Med, 1995, 333(26):1757-1763.
26. GALINDO-GALLEGO M., FERNÁNDEZ-ACEÑERO M. J., SANZ-ORTEGA J., ALJAMA A., LÓPEZ-ELZAURDIA C., Prognostic significance of microvascular counts in rectal carcinoma, Pathol Res Pract, 2000, 196(9):607-612.
27. SHIJUBO N., KOJIMA H., NAGATA M., OHCHI T., SUZUKI A., ABE S., SATO N., Tumor angiogenesis of non-small cell lung cancer, Microsc Res Tech, 2003, 60(2):186-198.
28. MACCHIARINI P., FONTANINI G., HARDIN M. J., SQUARTINI F., ANGELETTI C. A., Relation of neovascularisation to metastasis of non-small-cell lung cancer, Lancet, 1992, 340(8812):145-146.
29. QIN L. X., TANG Z. Y., The prognostic molecular markers in hepatocellular carcinoma, World J Gastroenterol, 2002, 8(3):385-392.
30. ZETTERSTEN E., SHAIKH L., RAMIREZ R., KASHANI-SABET M. Prognostic factors in primary cutaneous melanoma, Surg Clin North Am, 2003, 83(1):61-75.
31. BONO A. V., CELATO N., COVA V., SALVADORE M., CHINETTI S., NOVARIO R., Microvessel density in prostate carcinoma, Prostate Cancer Prostatic Dis, 2002, 5(2):123-127.
32. KATO T., KIMURA T., ISHII N., FUJII A., YAMAMOTO K., KAMEOKA S., NISHIKAWA T., KASAJIMA T., The methodology of quantitation of microvessel density and prognostic value of neovascularization associated with long-term survival in Japanese patients with breast cancer, Breast Cancer Res Treat, 1999, 53(1):19-31.
33. WEIDNER N., SEMPLE J. P., WELCH W. R., FOLKMAN J., Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma, N Engl J Med,1991, 324(1):1-8.
34. LEEK R. D., The prognostic role of angiogenesis in breast cancer, Anticancer Res, 2001, 21(6B):4325-4331.
35. SAARISTO A., KARPANEN T., ALITALO K., Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis, Oncogene, 2000, 19(53):6122-6129.
36. GASPARINI G., Clinical significance of determination of surrogate markers of angiogenesis in breast cancer, Crit Rev Oncol Hematol, 2001, 37(2):97-114.
37. GOULDING H., ABDUL RASHID N. F., ROBERTSON J. F., BELL J. A., ELSTON C. W., BLAMEY R. W., ELLIS I. O., Assessment of angiogenesis in breast carcinoma: an important factor in prognosis?, Hum Pathol, 1995, 26(11):1196-1200.
38. VAN HOEF M. E., KNOX W. F., DHESI S. S., HOWELL A., SCHOR A. M., Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer, Eur J Cancer, 1993, 29A(8):1141-1145.
39. SHARMA S., SHARMA M. C., SARKAR C., Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangio- genesis, Histopathology, 2005, 46(5):481-489.
40. GAJDOS C., TARTTER P. I., BLEIWEISS I. J., HERMANN G., DE CSEPEL J., ESTABROOK A., RADEMAKER A. W., Mammographic appearance of nonpalpable breast cancer reflects pathologic characteristics, Ann Surg, 2002, 235(2):246-251.
41. VERKOOIJEN H. M.; CORE BIOPSY AFTER RADIOLOGICAL LOCALISATION (COBRA) STUDY GROUP, Diagnostic accuracy of stereotactic large-core needle biopsy for nonpalpable breast disease: results of a multicenter prospective study with 95% surgical confirmation, Int J Cancer, 2002, 99(6):853-859.
42. PARKER S. H., LOVIN J. D., JOBE W. E., BURKE B. J., HOPPER K. D., YAKES W. F., Nonpalpable breast lesions: stereotactic automated large-core biopsies, Radiology, 1991, 180(2):403-407.
43. ELVECROG E. L., LECHNER M. C., NELSON M. T., Nonpalpable breast lesions: correlation of stereotaxic large- core needle biopsy and surgical biopsy results, Radiology, 1993, 188(2):453-455.
44. DRONKERS D. J., Stereotaxic core biopsy of breast lesions, Radiology, 1992, 183(3):631-634.
45. rd edition, American College of Radiology Reston, VA, 1998.
46. ALLRED D. C., HARVEY J. M., BERARDO M., CLARK G. M., Prognostic and predictive factors in breast cancer by immunohistochemical analysis, Mod Pathol, 1998, 11(2):155-168.
47. LACASSAGNEA.,Hormonalpathogenesisof adenocarcinoma of the breast, Am J Cancer, 1936, 27:217-225.
48. ***, Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group, Lancet, 1992, 339(8785):71-85.
49. FISHER B., COSTANTINO J. P., WICKERHAM D. L., REDMOND C. K., KAVANAH M., CRONIN W. M., VOGEL V., ROBIDOUX A., DIMITROV N., ATKINS J., DALY M., WIEAND S., TAN-CHIU E., FORD L., WOLMARK N., Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, J Natl Cancer Inst (Bethesda), 1998, 90(18):1371-1388.
50. BAUM M., BUDZAR A. U., CUZICK J., FORBES J., HOUGHTON J. H., KLIJN J. G., SAHMOUD T.; ATAC TRIALISTS' GROUP, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial, Lancet, 2002, 359(9324):2131-2139.
51. OSBORNE C. K., Tamoxifen in the treatment of breast cancer, N Engl J Med, 1998, 339(22):1609-1618.
52. HOWELL A., DEFRIEND D., ROBERTSON J., BLAMEY R., WALTON P., Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer, Lancet, 1995, 345():29-30.
53. OSBORNE C. K., CORONADO E., ALLRED D. C., WIEBE V., DEGREGORIO M., Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen, J Natl Cancer Inst (Bethesda), 1991, 83(20):1477-1482.
54. OSBORNE C. K., FUQUA S. A., Mechanisms of tamoxifen resistance, Breast Cancer Res Treat, 1994, 32(1):49-55.
55. OSBORNE C. K., JARMAN M., MCCAGUE R., CORONADO E. B., HILSENBECK S. G., WAKELING A. E., The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth, Cancer Chemother Pharmacol, 1994, 34(2):89-95.
56. WIEBE V. J.,OSBORNE C. K., FUQUA S. A. W., DEGREGORIO M. W., Tamoxifen resistance in breast cancer, Crit Rev Oncol Hematol, 1993, 14(3):173-188.
57. CLARKE R., BRÜNNER N., Acquired estrogen independence and antiestrogen resistance in breast cancer. Estrogen receptor driven phenotypes?, Trends Endocrinol Metab, 1996, 7(8):291-301.
58. TAKIMOTO G. S., GRAHAM J. D., JACKSON T. A., TUNG L., POWELL R. L., HORWITZ L. D., HORWITZ K. B., Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors, J Steroid Biochem Mol Biol, 1999, 69(1-6):45-50.
59. TZAHAR E., YARDEN Y., The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands, Biochim Biophys Acta, 1998, 1377(1):M25-M37.
60. ND, STERN D. F., Specificity within the EGF family/ErbB receptor family signaling network, Bioessays, 1998, 20(1):41-48.
61. BENZ C. C., SCOTT G. K., SARUP J. C., JOHNSON R. M., TRIPATHY D., CORONADO E., SHEPARD H. M., OSBORNE C. K., Estrogen-dependent,tamoxifen-resistanttumorigenic growth of MCF-7 cells transfected with HER2/neu, Breast Cancer Res Treat, 1992, 24(2):85-95.
62. PIETRAS R. J., ARBOLEDA J., REESE D. M., WONGVIPAT N., PEGRAM M. D., RAMOS L., GORMAN C. M., PARKER M. G., SLIWKOWSKI M. X., SLAMON D. J., HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone- independent growth in human breast cancer cells, Oncogene, 1995, 10(12):2435-2446.
63. LIU Y., EL-ASHRY D., CHEN D., DING I. Y. F., KERN F. G., MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen- depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo, Breast Cancer Res Treat, 1995, 34(2):97-117.
64. HARRIS A. L., NICHOLSON S., SAINSBURY J. R., FARNDON J., WRIGHT C., Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu, J Steroid Biochem, 1989, 34(1-6):123-131.
65. WRIGHT C., NICHOLSON S., ANGUS B., SAINSBURY J. R., FARNDON J., CAIRNS J., HARRIS A. L., HORNE C. H., Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer, Br J Cancer, 1992, 65(1):118-121.
66. BORG A., BALDETORP B., FERNÖ M., KILLANDER D., OLSSON H., RYDÉN S., SIGURDSSON H., ERBB2 amplification is associated with tamoxifen resistance in steroid- receptor positive breast cancer, Cancer Lett, 1994, 81(2):137-144.
67. LEITZEL K., TERAMOTO Y., KONRAD K., CHINCHILLI V. M., VOLAS G., GROSSBERG H., HARVEY H., DEMERS L., LIPTON A., Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer, J Clin Oncol, 1995, 13(5):1129-1135.
68. CARLOMAGNO C., PERRONE F., GALLO C., DE LAURENTIIS M., LAURIA R., MORABITO A., PETTINATO G., PANICO L., D'ANTONIO A., BIANCO A. R., DE PLACID S., c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases, J Clin Oncol, 1996, 14(10):2702-2708.
69. YAMAUCHI H., O'NEILL A, GELMAN R., CARNEY W., TENNEY D. Y., HÖSCH S., HAYES D. F., Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein, J Clin Oncol, 1997, 15(7):2518-2525.
70. BERNS E. M., FOEKENS J. A., VAN STAVEREN I. L., VAN PUTTEN W. L., DE KONING H. Y., PORTENGEN H., KLIJN J. G., Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment, Gene, 1995, 159(1):11-18.
71. ARCHER S. G., ELIOPOULOS A., SPANDIDOS D., BARNES D., ELLIS I. O., BLAMEY R. W., NICHOLSON R. I., ROBERTSON J. F., Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy, Br J Cancer, 1995, 72(5):1259-1266.
72. HOUSTON S. J., PLUNKETT T. A., BARNES D. M., SMITH P., RUBENS R. D., MILES D. W., Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer, Br J Cancer, 1999, 79(7-8):1220-1226.
73. ELLEDGE R. M., GREEN S., CIOCCA D., PUGH R., ALLRED D. C., CLARK G. M., HILL J., RAVDIN P., O'SULLIVAN J., MARTINO S., OSBORNE C. K., HER-2 expression and response to tamoxifen in estrogen receptor- positive breast cancer: a Southwest Oncology Group Study, Clin Cancer Res, 1998, 4(1):7-12.
74. JANES P. W., DALY R. J., DEFAZIO A., SUTHERLAND R. L., Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2, Oncogene, 1994, 9(12):3601-3608.
75. KATO S., ENDOH H., MASUHIRO Y., KITAMOTO T., UCHIYAMA S., SASAKI H., MASUSHIGE S., GOTOH Y., NISHIDA E., KAWASHIMA H., METZGER D., CHAMBON P., Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase, Science, 1995, 270(5241):1491-1494.
76. BUNONE G., BRIAND P. A., MIKSICEK R. J., PICARD D., Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation, EMBO J, 1996, 15(9):2174-2183.
77. HANAHAN D., WEINBERG R. A., The hallmarks of cancer, Cell, 2000, 100(1):57-70.
78. WEIDNER N., FOLKMAN J., Tumoral vascularity as a
79. FOLKMAN J., Fundamental concepts of the angiogenic prognostic factor in cancer, Important Adv Oncol,process, Curr Mol Med, 2003, 3(7):643-651. 1996:167-190.